PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2017

Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model.

Mouse / Chemical/toxin

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 28291245 ↗2017Reported benefit

Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model.

MouseChemical/toxinC57BL/6malen = n = 5 per groupintraperitoneal5 mg/kg in 1 per cent DMSO and 5 per cent beta-hydroxycyclo…post-disease, on day 2 and day 3 after carbon tetrachloride given at day 1

Model: Single intraperitoneal injection of carbon tetrachloride 1 mL/kg in olive oil at day 1

Post-disease BIBF1120 at 5 mg/kg reduced collagen I, desmin, alpha-smooth muscle actin, extracellular matrix and adhesion proteins, TIMP1, angiogenic markers and pro-inflammatory cytokines with a shift toward M2 macrophages, although alanine aminotransferase levels were unchanged.

Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.